Figen Batioglu, MD, Emin Ozmert, MD, Department of Ophthalmology, Ankara University, Ankara, Turkey


To evaluate the efficacy and safety of intravitreal triamcinolone acetonide for diabetic macular edema.


Twenty-six eyes of 20 diabetic patients with macular edema that failed to respond to previous laser photocoagulation were included in the study. After a complete ophthalmic examination, central macular thickness measurements were taken from optical coherence tomography (OCT) scans. Twenty-three eyes were offered intravitreal injection of 4mg (0.1 ml) triamcinolone acetonide as a primary procedure and the remaining three received the injection at the end of vitreoretinal surgery. During the follow-up, visual acuity, quantitative change in OCT macular thickening were assessed and potential complications were monitored. Statistical analysis was performed in eyes which had a followup of at least 3 months.


The mean follow-up period was 4.6 months (range: 1- 14 months). Baseline central macular thickness averaged 828.13 micron. At the third day, a reduction in the mean central macular thickness of 36.6% from 828.13 micron to 524.8 micron was obtained.
At 1 and 3 months, macular thickness measurements decreased by 58% (347.73 micron), and 48.7% (425.2 micron) respectively. The mean central macular thickness which was obtained at 3 Р15 days, 1 and 3 months was significantly different than the baseline measurement. During the follow-up, five (19.2%) patients developed intraocular pressure values higher than 21mmHg, which could be controlled by topical antiglaucomatous treatment. Four (15%) patients required retreatment of intravitreal injections.


Optical coherence tomography demonstrated significant anatomic improvement in the majority of patients with diabetic macular edema treated with intravitreal injection of triamcinolone acetonide in the short-term.

Take-home message:

Although short-term results are encouraging, further studies are necessary to assess the long-term efficacy and safety, and the need for retreatment of intravitreal triamcinole injections.